Clinical Trials Directory

Trials / Completed

CompletedNCT00742976

Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients

Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention and Weight in Type 2 Diabetic Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Rigshospitalet, Denmark · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Hypothesis: Changing type 2 patients treatment from Insulin Insulatard to Insulin Detemir will increase their excretion of sodium in the urine and thereby decrease their extracellular volume and body weight. 24 patients are divided into 2 groups and their insulin treatment is shifted while their body composition, sodium excretion, weight and extracellular volume is monitored.

Detailed description

Type 2 diabetic patients experience weight gain when receiving insulin treatment. There has been reports that the weight gain is less or absent when patients are treated with Insulin Detemir. Patients with diabetes have increased total body sodium and increased extracellular volume. We hypothesize that part of the weight gain seen is due to increase in extracellular volume and that the lesser weight gain seen in patients treated with Detemir is due to an lesser increase in extracellular volume. We believe that the cause of this difference is the different pharmacokinetic properties of insulin Detemir. Insulin Detemir i protein bound and is therefore not excreted in the kidneys. This may cause less sodium reabsorption, than with other insulins, and therefore less increase in extracellular volume. We test this hypothesis by examining urinary sodium excretion, extracellular volume by GFR measurements, Body composition by DEXA scan, body weight, and 24 hour blood pressure.In patients that are changed from Insulin Insulatard to Insulin Detemir and back.

Conditions

Interventions

TypeNameDescription
DRUGInsulin Detemir; Insulin InsulatardDosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
DRUGInsulin Detemir, Insulin InsulatardFixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.

Timeline

Start date
2008-06-01
Primary completion
2009-12-01
Completion
2009-12-01
First posted
2008-08-28
Last updated
2010-01-20

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT00742976. Inclusion in this directory is not an endorsement.